NCT07425392

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 720 (estimated)
• Sponsor: Vaxcyte, Inc. · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.

Conditions

• Pneumococcal Vaccines

Interventions

Type	Name	Description
BIOLOGICAL	31-valent pneumococcal conjugate vaccine	0.5 mL of VAX-31 will be administered into the deltoid muscle
BIOLOGICAL	PCV20	0.5 mL of the 20-valent pneumococcal conjugate vaccine will be administered into the deltoid muscle

Timeline

• Start date: 2026-02-09
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2026-02-20
• Last updated: 2026-03-18

Locations

30 sites across 1 country: United States

Regulatory

• FDA-regulated drug study